v3.26.1
LICENSE, COLLABORATION AND OTHER REVENUE - MTPC Collaboration Agreement - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 11, 2015
USD ($)
performance_obligation
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenues   $ 49,128 $ 62,472 $ 102,672 $ 119,808  
Accounts receivable, net   53,506   53,506   $ 47,031
Payables   9,422   9,422   $ 21,185
Revenue recognized   0 0 0 0  
Royalty payments            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenues   100 0 100 0  
Tanabe Pharma Corporation            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenues $ 9,400          
Tanabe Pharma Corporation | Royalty payments            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenues   400 500 800 900  
Tanabe Pharma Corporation | Regulatory Milestone Payments            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone revenue $ 25,000     25,000    
Tanabe Pharma Corporation | Development And Commercialize Collaboration Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of performance obligations | performance_obligation 2          
Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront cash payment received $ 20,000          
Cost of research services 20,500          
Milestone revenue $ 10,000          
Deferred revenue   0   0    
Accounts receivable, net   0   0    
Payables   0   0    
Contract asset   400   400    
Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Deferred revenue   0   0    
Accounts receivable, net   0   0    
Payables   0   0    
Revenue recognized   $ 0 $ 0 $ 0 $ 0